LEXX Fundamental Analysis - LEXARIA BIOSCIENCE CORP

Fundamental Rating

Taking everything into account, LEXX scores 3 out of 10 in our fundamental rating. LEXX was compared to 191 industry peers in the Pharmaceuticals industry. While LEXX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LEXX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LEXX has reported negative net income.

In the past year LEXX has reported a negative cash flow from operations.

In the past 5 years LEXX always reported negative net income.

In the past 5 years LEXX always reported negative operating cash flow.

1.2 Ratios

LEXX has a Return On Assets of -285.07%. This is amonst the worse of the industry: LEXX underperforms 93.19% of its industry peers.

LEXX has a worse Return On Equity (-398.09%) than 78.01% of its industry peers.

		Industry Rank	Sector Rank
ROA	-285.07%
ROE	-398.09%
ROIC	N/A

ROA(3y)-188.88%

ROA(5y)-137.97%

ROE(3y)-229.76%

ROE(5y)-162.22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LEXX has a Gross Margin of 99.62%. This is amongst the best in the industry. LEXX outperforms 97.91% of its industry peers.

LEXX's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for LEXX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	99.62%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y12.9%

GM growth 5Y7.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LEXX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LEXX has been increased compared to 1 year ago.

LEXX has more shares outstanding than it did 5 years ago.

There is no outstanding debt for LEXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

LEXX has an Altman-Z score of -23.63. This is a bad value and indicates that LEXX is not financially healthy and even has some risk of bankruptcy.

LEXX has a worse Altman-Z score (-23.63) than 87.43% of its industry peers.

LEXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-23.63

ROIC/WACCN/A

WACC8.38%

2.3 Liquidity

LEXX has a Current Ratio of 2.32. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.

LEXX's Current ratio of 2.32 is in line compared to the rest of the industry. LEXX outperforms 43.46% of its industry peers.

LEXX has a Quick Ratio of 2.32. This indicates that LEXX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.32, LEXX is in line with its industry, outperforming 48.69% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.32
Quick Ratio	2.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LEXX have decreased strongly by -41.30% in the last year.

Looking at the last year, LEXX shows a very strong growth in Revenue. The Revenue has grown by 52.04%.

LEXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.89% yearly.

EPS 1Y (TTM)-41.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%7.14%

Revenue 1Y (TTM)52.04%

Revenue growth 3Y39.51%

Revenue growth 5Y17.89%

Sales Q2Q%107.14%

3.2 Future

Based on estimates for the next years, LEXX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.83% on average per year.

Based on estimates for the next years, LEXX will show a very strong growth in Revenue. The Revenue will grow by 189.59% on average per year.

EPS Next Y18.4%

EPS Next 2Y-8.49%

EPS Next 3Y29.83%

EPS Next 5YN/A

Revenue Next Year17.26%

Revenue Next 2Y44.81%

Revenue Next 3Y-25.99%

Revenue Next 5Y189.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEXX. In the last year negative earnings were reported.

Also next year LEXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

LEXX's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-8.49%

EPS Next 3Y29.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LEXX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (12/30/2025, 4:59:56 PM)

After market: 0.53 -0.01 (-1.85%)

0.54

-0.02 (-3.57%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-26 2025-11-26/amc

Earnings (Next)01-08 2026-01-08

Inst Owners7.73%

Inst Owner Change-26.67%

Ins Owners6.36%

Ins Owner Change5.43%

Market Cap12.00M

Revenue(TTM)705.90K

Net Income(TTM)-11.90M

Analysts82.5

Price Target5.44 (907.41%)

Short Float %2.97%

Short Ratio0.88

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-6.38%

Min EPS beat(2)-31.41%

Max EPS beat(2)18.65%

EPS beat(4)2

Avg EPS beat(4)-9.59%

Min EPS beat(4)-31.41%

Max EPS beat(4)18.65%

EPS beat(8)3

Avg EPS beat(8)-7.65%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)55.65%

Min Revenue beat(2)24.52%

Max Revenue beat(2)86.78%

Revenue beat(4)4

Avg Revenue beat(4)54.03%

Min Revenue beat(4)24.52%

Max Revenue beat(4)86.78%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-11.11%

EPS NQ rev (1m)-3.03%

EPS NQ rev (3m)-3.03%

EPS NY rev (1m)0%

EPS NY rev (3m)3.11%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	17.01
P/FCF	N/A
P/OCF	N/A
P/B	4.02
P/tB	4.48
EV/EBITDA	N/A

EPS(TTM)-0.65

EYN/A

EPS(NY)-0.53

Fwd EYN/A

FCF(TTM)-0.48

FCFYN/A

OCF(TTM)-0.47

OCFYN/A

SpS0.03

BVpS0.13

TBVpS0.12

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-285.07%
ROE	-398.09%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	99.62%
FCFM	N/A

ROA(3y)-188.88%

ROA(5y)-137.97%

ROE(3y)-229.76%

ROE(5y)-162.22%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y12.9%

GM growth 5Y7.02%

F-Score4

Asset Turnover0.17

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	276.77%
Cap/Sales	34.42%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.32
Quick Ratio	2.32
Altman-Z	-23.63

F-Score4

WACC8.38%

ROIC/WACCN/A

Cap/Depr(3y)212.54%

Cap/Depr(5y)178.07%

Cap/Sales(3y)49.65%

Cap/Sales(5y)45.86%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-41.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%7.14%

EPS Next Y18.4%

EPS Next 2Y-8.49%

EPS Next 3Y29.83%

EPS Next 5YN/A

Revenue 1Y (TTM)52.04%

Revenue growth 3Y39.51%

Revenue growth 5Y17.89%

Sales Q2Q%107.14%

Revenue Next Year17.26%

Revenue Next 2Y44.81%

Revenue Next 3Y-25.99%

Revenue Next 5Y189.6%

EBIT growth 1Y-106.54%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-107.74%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-110.74%

OCF growth 3YN/A

OCF growth 5YN/A

LEXARIA BIOSCIENCE CORP / LEXX FAQ

Can you provide the ChartMill fundamental rating for LEXARIA BIOSCIENCE CORP?

ChartMill assigns a fundamental rating of 3 / 10 to LEXX.

Can you provide the valuation status for LEXARIA BIOSCIENCE CORP?

ChartMill assigns a valuation rating of 1 / 10 to LEXARIA BIOSCIENCE CORP (LEXX). This can be considered as Overvalued.

What is the profitability of LEXX stock?

LEXARIA BIOSCIENCE CORP (LEXX) has a profitability rating of 1 / 10.

What is the expected EPS growth for LEXARIA BIOSCIENCE CORP (LEXX) stock?

The Earnings per Share (EPS) of LEXARIA BIOSCIENCE CORP (LEXX) is expected to grow by 18.4% in the next year.

LEXARIA BIOSCIENCE CORP (LEXX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

LEXARIA BIOSCIENCE CORP / LEXX FAQ

Can you provide the ChartMill fundamental rating for LEXARIA BIOSCIENCE CORP?

Can you provide the valuation status for LEXARIA BIOSCIENCE CORP?

What is the profitability of LEXX stock?

What is the expected EPS growth for LEXARIA BIOSCIENCE CORP (LEXX) stock?